Enveric Biosciences, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ENVB Nasdaq 2834 www.enveric.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enveric Biosciences, Inc.

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series - Sep 15th, 2026 6:00 am
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference - Sep 1st, 2026 6:30 am
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 - Aug 14th, 2026 2:05 pm
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003 - Aug 5th, 2026 6:00 am
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development - Jul 28th, 2026 6:00 am
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit - Jun 29th, 2026 6:00 am
Enveric Biosciences Announces Participation in 2026 BIO International Convention - Jun 16th, 2026 7:28 am
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day - Jun 9th, 2026 6:00 am
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 - Jun 2nd, 2026 6:00 am
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors - Apr 28th, 2026 5:33 am